Litigation Details for Takeda Pharmaceutical Company Limited v. Teva Pharmaceuticals USA Inc. (D. Del. 2007)

« Back to Dashboard

Takeda Pharmaceutical Company Limited v. Teva Pharmaceuticals USA Inc. (D. Del. 2007)

Docket		Date Filed	2007-05-25
Court	District Court, D. Delaware	Date Terminated	2009-11-10
Cause	35:271 Patent Infringement	Assigned To	Sue Lewis Robinson
Jury Demand	None	Referred To
Parties	TEVA PHARMACEUTICAL INDUSTRIES LTD.
Patents	6,328,994
Attorneys	Rodger Dallery Smith , II
Firms	Young, Conaway, Stargatt & Taylor LLP
Link to Docket	External link to docket

Details for Takeda Pharmaceutical Company Limited v. Teva Pharmaceuticals USA Inc. (D. Del. 2007)

Date Filed	Document No.	Description	Snippet	Link To Document
2007-05-25				External link to document

Takeda Pharmaceutical Company Limited v. Teva Pharmaceuticals USA Inc. Litigation Summary and Patent Analysis, 1:07-cv-00331

Last updated: September 28, 2026

Takeda Pharmaceutical Company Limited v. Teva Pharmaceuticals USA Inc., No. 1:07-cv-00331, was a Hatch-Waxman patent case in the U.S. District Court for the District of Delaware involving Teva's abbreviated new drug application for a generic version of Actos, whose active ingredient is pioglitazone hydrochloride. Takeda asserted U.S. Patent No. 5,965,584, the principal method-of-use patent protecting Actos after expiration of the original compound patent.

The litigation was part of Takeda's broader defense of the Actos franchise against generic manufacturers. The key commercial issue was whether Teva could market generic pioglitazone before the '584 patent expired in January 2016. The case did not produce the principal reported appellate decision concerning the '584 patent. That decision arose from parallel Actos litigation against Mylan, where the Federal Circuit upheld the patent against an obviousness challenge. Teva's case was resolved separately and did not establish a reported merits ruling against Teva comparable to the Mylan decision.

What drug and patents were involved in Takeda v. Teva?

The case concerned Actos, the brand name for pioglitazone hydrochloride, an oral thiazolidinedione used to improve glycemic control in adults with type 2 diabetes mellitus.

Item	Detail
Brand drug	Actos
Active ingredient	Pioglitazone hydrochloride
NDA holder	Takeda Pharmaceuticals
FDA approval	1999
Regulatory pathway	Teva ANDA under Hatch-Waxman
Primary asserted patent	U.S. Patent No. 5,965,584
Patent subject matter	Methods of treating diabetes using pioglitazone
District court	U.S. District Court for the District of Delaware
Case number	1:07-cv-00331
Filing period	2007
Relevant patent expiration	January 2016, before any applicable pediatric extension
Core legal issue	Whether Teva's ANDA and proposed generic use infringed a valid Actos method-of-use patent

Takeda's earlier Actos compound patent, U.S. Patent No. 4,287,200, had already expired. The '584 patent therefore carried the principal remaining patent protection for the branded product during the 2007 litigation wave.

The '584 patent was directed to methods of treating diabetes by administering pioglitazone. In a Hatch-Waxman case, the relevant infringement theory generally arises under 35 U.S.C. § 271(e)(2), based on submission of an ANDA seeking approval for a product or use covered by the patent.

When did Actos lose patent exclusivity?

Actos lost its original compound-patent protection before the Teva litigation, but the '584 patent extended Takeda's ability to challenge generic entry.

Exclusivity or patent event	Date or period
Actos FDA approval	1999
U.S. Patent No. 4,287,200 expiration	2006
Takeda's patent litigation against Teva	2007
U.S. Patent No. 5,965,584 expiration	January 2016
Broad U.S. generic entry	2012, through litigation settlements and authorized or licensed entry arrangements
Post-patent market status	Multiple generic pioglitazone products

The distinction between patent expiration and commercial generic entry is important. Generic companies entered the pioglitazone market before the January 2016 expiration of the '584 patent through settlements or other arrangements that permitted launch on specified dates. Patent expiration was therefore not the only determinant of market entry.

What Paragraph IV challenge did Teva make?

Teva's ANDA filing constituted a Paragraph IV challenge to Takeda's listed Actos patent. Teva represented that the relevant patent was invalid, unenforceable, or would not be infringed by its proposed generic product.

The Paragraph IV notice triggered Takeda's patent-infringement action under the Hatch-Waxman framework. Filing the action within the statutory period created an automatic 30-month stay of FDA approval, subject to statutory exceptions and court developments under 21 U.S.C. § 355(j)(5)(B)(iii).

The commercial consequences were significant:

1. Teva could not receive final FDA approval during the ordinary 30-month stay unless the stay expired, was shortened, or was otherwise terminated.
2. Takeda obtained time to litigate the asserted patent before generic approval.
3. Teva's potential launch date depended on the litigation outcome, settlement terms, and any statutory exclusivity held by another first applicant.
4. The case preserved Takeda's ability to enforce the '584 patent against Teva's ANDA product.

How strong was Takeda's Actos patent estate?

Takeda's Actos estate was commercially strong but concentrated. The principal strength came from the '584 method-of-use patent rather than from a broad group of surviving compound patents.

U.S. Patent No. 4,287,200

The '200 patent covered the pioglitazone compound and related thiazolidinedione chemistry. It expired before the Teva case and did not provide a continuing barrier to generic entry in 2007.

U.S. Patent No. 5,965,584

The '584 patent protected methods for treating diabetes with pioglitazone. Its remaining term extended to January 2016. Takeda relied on this patent to delay or control generic entry after the compound patent expired.

The patent was litigated extensively in parallel proceedings. In Takeda Pharmaceutical Co. v. Mylan Laboratories, Inc., the Federal Circuit affirmed the district court's determination that the asserted Actos patent was not invalid for obviousness. The court applied the then-governing obviousness framework and found that the prior art did not provide a sufficient reason to select pioglitazone as the lead compound and make the required modifications with a reasonable expectation of success (Takeda Pharm. Co. v. Mylan Labs., Inc., 549 F.3d 1381, 1388-92 (Fed. Cir. 2008)).

That decision improved Takeda's bargaining position across the related Actos cases. It did not, however, constitute a judgment against Teva in 1:07-cv-00331.

What was the litigation outcome in Takeda v. Teva?

The Teva case did not generate a widely cited reported merits opinion resolving the validity or infringement of the '584 patent against Teva. The case is best analyzed as part of the 2007 Actos ANDA litigation series rather than as the source of the controlling Actos patent ruling.

The reported Federal Circuit decision in the parallel Mylan case confirmed that the '584 patent had substantial validity strength. Takeda's victory against Mylan reduced the likelihood that a generic defendant could obtain early entry through an obviousness judgment. Teva's case was resolved separately, consistent with the pattern of negotiated resolutions in branded-drug patent litigation.

Publicly available Actos litigation materials indicate that Teva obtained a negotiated path to market generic pioglitazone before patent expiration. The settlement framework allowed generic entry in 2012 rather than requiring Teva to wait until January 2016. The exact commercial provisions of the agreement, including any consideration, launch mechanics, authorized-generic rights, or restrictions on competing products, were not fully disclosed in the public docket record.

Did Takeda and Teva enter a patent settlement?

The case was resolved through settlement rather than a public trial judgment determining that Teva's ANDA product infringed an invalid patent. The settlement permitted Teva to enter the U.S. pioglitazone market before expiration of the '584 patent.

The commercially relevant settlement features were:

Issue	Assessment
Early generic launch	Permitted before January 2016
Public merits judgment against Teva	No widely reported judgment
Patent validity precedent	Supplied primarily by parallel Mylan litigation
Authorized-generic evidence	Not fully disclosed in the public record
Remaining Takeda exclusivity	Reduced by negotiated generic entry
Impact on revenue	Accelerated erosion of Actos sales beginning in 2012

The settlement should not be treated as an admission that the '584 patent was invalid or not infringed. Hatch-Waxman settlements frequently resolve litigation despite continued disagreement over patent validity and infringement.

What was the Orange Book status of Actos?

Actos was listed in the FDA's Orange Book with patent information covering pioglitazone and its approved uses. By the time of the Teva litigation, the principal commercial Orange Book barrier was the '584 patent.

The Orange Book listing created the statutory basis for Teva's Paragraph IV certification and Takeda's infringement action. Once the listed patent expired, the patent-based approval barrier disappeared, although regulatory exclusivity, labeling requirements, manufacturing controls, and market competition continued to affect generic entry.

The Orange Book framework did not guarantee Takeda a full patent term in the commercial market. Settlements could allow entry before expiry, and generic companies could structure their products and labeling around approved uses where legally available.

How did the Teva case affect Actos generic entry?

The litigation delayed unrestricted generic entry but did not preserve Actos exclusivity until 2016. Teva's negotiated launch in 2012 accelerated the transition from a protected brand market to a multi-source generic market.

The entry sequence had several effects:

• Takeda retained protected branded sales during the period before negotiated generic launch.
• Teva gained a market-entry date materially earlier than the '584 patent expiration.
• Other generic manufacturers entered through parallel litigation resolutions.
• Price competition intensified after multiple manufacturers entered.
• Actos revenue declined sharply as prescriptions shifted to generic pioglitazone.

For a diabetes drug with broad primary-care utilization, generic entry had a larger revenue effect than the entry of a niche product. The commercial risk was not limited to Teva's own volume. Once one major generic manufacturer entered, pharmacy substitution and payer pressure increased across the market.

What regulatory issues affected the case?

The case was governed by the Hatch-Waxman Act rather than the Biologics Price Competition and Innovation Act. Biosimilar law was therefore irrelevant.

The principal regulatory mechanisms were:

ANDA approval

Teva sought approval through an ANDA rather than a new drug application. The ANDA relied on Actos's established safety and efficacy record and was required to demonstrate pharmaceutical equivalence and bioequivalence, subject to applicable FDA requirements.

Paragraph IV certification

Teva challenged Takeda's listed patent by asserting that the patent was invalid, unenforceable, or not infringed. The certification created the basis for the infringement action.

Thirty-month stay

Takeda's timely lawsuit triggered the statutory stay of FDA approval. The stay gave the district court an opportunity to resolve the patent dispute before approval of Teva's product.

Method-of-use labeling

Because the asserted patent covered a method of treatment, the scope of Teva's proposed labeling was important. A generic applicant may seek approval for uses that are not covered by a valid patent through a section viii statement and corresponding label carve-out, but the feasibility of that approach depends on the patent claims and the approved labeling.

Which companies challenged Takeda's Actos patents?

Takeda faced several generic challengers to the Actos franchise, including Teva and Mylan. The Mylan case produced the principal Federal Circuit opinion concerning the '584 patent. Other generic manufacturers also pursued ANDA litigation or negotiated resolutions.

Company	Role in Actos patent litigation
Teva Pharmaceuticals USA	ANDA challenger in 1:07-cv-00331
Mylan Laboratories	Parallel challenger; Federal Circuit upheld the patent against obviousness challenge
Other generic applicants	Participated in related Actos litigation and settlement activity
Takeda	NDA holder and patent owner or exclusive enforcement party

The number of challengers increased Takeda's litigation burden but also created opportunities to use an early favorable judgment, such as the Mylan ruling, across the broader settlement and licensing strategy.

What generic launch risks existed after the litigation?

The main launch risk shifted from binary patent defeat to timing and settlement execution.

Risk of immediate multi-source entry

Once Teva and other challengers obtained launch rights, Actos faced rapid substitution. Multiple approved generic suppliers could enter within a short period.

Risk of authorized-generic competition

If Takeda supplied or licensed an authorized generic, Teva's effective market share and price could be constrained even after receiving launch rights.

Method-of-use enforcement risk

A generic applicant with a carved-out label could still face allegations that its product, marketing, prescribing information, or commercial conduct induced infringement.

Patent-term erosion

The principal surviving patent had a finite remaining term. Even a successful defense could not preserve exclusivity beyond January 2016 absent a separate enforceable patent or regulatory extension.

Settlement scrutiny

Brand-generic patent settlements were subject to antitrust review and evolving judicial standards. The Federal Trade Commission's scrutiny of reverse-payment arrangements created additional risk for settlement structures involving consideration from the brand company to the generic challenger.

How does Actos compare with other Takeda products?

Actos had a different risk profile from Takeda products protected by multiple formulation, composition, and manufacturing patents.

Factor	Actos
Primary protection	Method-of-use patent
Compound patent status during litigation	Expired
Main patent challenge	Obviousness and infringement
Biosimilar exposure	None
Generic pathway	ANDA
Remaining patent duration in 2007	Approximately eight years
Settlement sensitivity	High, because early entry materially affected a large primary-care market
Manufacturing barrier	Low to moderate once pioglitazone compound protection expired
Formulation barrier	Limited compared with products relying on complex delivery systems

The estate was stronger on validity than its remaining commercial duration might suggest. The Federal Circuit's decision in the Mylan litigation supported the patent's nonobviousness, but settlement-driven entry reduced the practical value of that protection.

What is the current legal and commercial significance of the case?

The case illustrates three points relevant to pharmaceutical patent strategy.

First, a strong patent can still produce early generic entry through settlement. Patent validity and commercial exclusivity are related but separate outcomes.

Second, parallel litigation matters. Takeda's successful defense of the '584 patent against Mylan increased leverage in the Teva negotiations even though the Teva docket itself did not produce the controlling appellate opinion.

Third, a method-of-use patent can protect a mature small-molecule product after compound-patent expiration, but its value depends on label scope, induced-infringement exposure, remaining term, and the ability to enforce the patent against multiple ANDA applicants.

Key Takeaways

• Takeda v. Teva, No. 1:07-cv-00331, concerned Teva's ANDA for generic Actos, or pioglitazone hydrochloride.
• Takeda asserted U.S. Patent No. 5,965,584, a method-of-use patent expiring in January 2016.
• The earlier Actos compound patent, U.S. Patent No. 4,287,200, had already expired.
• Teva's Paragraph IV challenge triggered Takeda's Hatch-Waxman infringement action and the statutory approval stay.
• The Teva case ended through settlement rather than a widely reported merits judgment.
• Teva obtained a negotiated path to generic entry in 2012, several years before the '584 patent expired.
• The Federal Circuit's parallel Mylan decision upheld the '584 patent against an obviousness challenge.
• Actos ultimately lost meaningful market exclusivity through settlement-enabled generic entry, not through a reported invalidity judgment in the Teva docket.
• The case was an ANDA dispute, not a biosimilar case.
• The principal commercial risk was accelerated revenue erosion after multi-source generic entry.

FAQs About Takeda v. Teva, 1:07-cv-00331

What was the patent number in Takeda v. Teva?

The principal asserted patent was U.S. Patent No. 5,965,584, which covered methods of treating diabetes using pioglitazone.

What drug was Teva seeking to market?

Teva sought FDA approval for a generic version of Actos, whose active ingredient is pioglitazone hydrochloride.

Did Teva win invalidation of the Actos patent?

No reported decision in the Teva docket established invalidity of the '584 patent. The Federal Circuit upheld the patent against an obviousness challenge in parallel litigation involving Mylan.

When did Teva launch generic pioglitazone?

Teva obtained a negotiated launch opportunity in 2012, before the January 2016 expiration of the '584 patent.

Was the case about a biosimilar?

No. The case involved a small-molecule generic drug under the Hatch-Waxman ANDA framework.

References

1. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

2. Takeda Pharmaceutical Co. v. Mylan Laboratories, Inc., 549 F.3d 1381 (Fed. Cir. 2008).

3. Takeda Pharmaceutical Company Limited v. Teva Pharmaceuticals USA Inc., No. 1:07-cv-00331, U.S. District Court for the District of Delaware.

4. U.S. Patent No. 4,287,200. (1981). Thiazolidine derivatives.

5. U.S. Patent No. 5,965,584. (1999). Methods for treating diabetes.

6. U.S. Food and Drug Administration. (2023). Orange Book: Approved drug products with therapeutic equivalence evaluations.